RED

Redx Pharma is a clinical-stage biotechnology company dedicated to the discovery and development of novel targeted small molecule medicines for the treatment of cancer and fibrotic diseases. The company leverages its core strengths in medicinal chemistry and translational science to develop potentially best-in-class or first-in-class drug candidates against biologically validated targets. Its lead clinical programs include zelasudil (RXC007), a selective ROCK2 inhibitor for idiopathic pulmonary fibrosis, and RXC008, a GI-restricted pan-ROCK inhibitor for fibrostenotic Crohn's disease. Redx has established significant partnerships with major pharmaceutical companies, including AstraZeneca and Jazz Pharmaceuticals, to advance its diverse pipeline. Headquartered in the United Kingdom, the company continues to focus on addressing high unmet medical needs through innovative chemical design.